MB BChir

MB BChir

The degree granted by some medical schools in the UK, which is equivalent to MB BS, but incorrectly suggests that there are two degrees; the equivalent in many countries is MD (medical doctor), a title which in the UK is conferred upon a person who completed medical school with honours, as well as one or more additional years of study.
References in periodicals archive ?
Stephen Morrison graduated MB BChir from Clare College at Cambridge University in 1971, having obtained a BA Hons in medical sciences in 1968.
These positive data from more than 270 patients enrolled in the HOPE Study provide strong evidence that voxelotor, by significantly improving anemia and hemolysis, has the potential to be a disease-modifying treatment for SCD by preventing chronic organ damage and prolonging survival, said Jo Howard, MB BChir, MRCP, FRCPath, of Guys and St.
"2017 was a year of consistent and dynamic execution at Ovid Therapeutics," said Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid Therapeutics.
Effective immediately, Dr Namouni will be responsible for the execution of a comprehensive development strategy for the company's robust oncology pipeline,remain a member of the R&D leadership team as well as continue to report to its executive vice president, chief scientific officer, Francis Cuss, MB Bchir, FRCP.
Niall Moore, MA, MB BChir, FRCR, FRCP, is Associate Professor of Radiology, X-Ray Department, John Radcliffe Hospital, Headley Way, Headington, United Kingdom.
Z Nene, (1) BSc, MB ChB, Dip Palliative Med, DOH, MMed (O&G), FCOG (SA), Cert Reproductive Medicine (SA); G J Hofmeyr, (2) MB BCh, MRCOG, DSc; M Patel, (3) MB ChB, FCOG (SA), MMed (O&G), Cert Reproductive Medicine (SA); M Panday, (4) MB ChB, FCOG (SA); H Rees, (5) MB BChir, MA (Cantab), MRCGP, DCH, DRCOG; M Makua, (6) DLitt et Phil, MTech; Y Pillay, (6) PhD
Addressing the significant unmet need in fibrotic diseases is a key part of Bristol-Myers Squibbs strategy to build a sustainable and diversified portfolio of transformational medicines, said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer of Bristol-Myers Squibb.
'At Bristol-Myers Squibb, patients are the inspiration behind our pioneering research in the field of Immuno-Oncology, which has led to the approval of novel agents for the treatment of some of the hardest to treat cancers,' said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb.
Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb, said, Bristol-Myers Squibb is committed to leading scientific advances in immuno-oncology and our acquisition of Flexus will expand our innovative pipeline with an important approach to enhancing immune responses in cancer.
Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer at Bristol-Myers Squibb, said, 'Bristol-Myers Squibb's collaboration with DCRI reflects our commitment to providing broader, more timely access to important clinical trial information and serves as a catalyst to strengthening public confidence in medicines, advancing science and improving public health.'
Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb, stated : "Delivering innovative medicines that halt or slow the progression of fibrotic diseases is a key part of our R&D strategy to build a sustainable pipeline, said .